Veronique Debien, Medical Oncologist at Institut Bergonié, shared on LinkedIn:
“Precision medicine in oncology is becoming increasingly multidimensional, integrating molecular profiling with clinical pharmacology, PK/PD and dose optimization.
Pleased to share our new viewpoint from the EORTC – European Organisation for Research and Treatment of Cancer PAMM Group, discussing how these different dimensions can contribute to more personalized cancer treatment.
A topic particularly relevant to early drug development and closely connected to our work at our early phase unit, Unité de Phases Précoces – Institut Bergonié CLIP2
Many thanks to all co-authors and collaborators for their contribution to this work.”
Title: Personalized medicine, scientific revolution or self-serving illusion: viewpoint from EORTC-PAMM Group
Authors: V. Debien, A. Geraud-Cremieux, M. Le Grand, D. Carbone, I. Garajova, C. Pecoraro, E. Pasquier, G.J. Peters, E. Giovannetti, M. Centanni, J. Ciccolini
Other articles featuring Veronique Debien on OncoDaily.